Last update 24 Feb 2026

JTT-861

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
JTT-861
Target
PDHK
Action
inhibitors
Mechanism
PDHK inhibitors(Pyruvate dehydrogenase kinase inhibitors)
Therapeutic Areas
Cardiovascular Diseases
Active Indication
Heart failure with reduced ejection fractionHeart Failure, SystolicChronic heart failure
Inactive Indication-
Originator Organization
Akros Pharma, Inc.
Active Organization
Akros Pharma, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with JTT-861
NCT06017609
/ Active, not recruitingPhase 2
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of JTT-861 Administered for 12 Weeks in Subjects With Heart Failure With Reduced Ejection Fraction
100 Clinical Results associated with JTT-861
Login to view more data
100 Translational Medicine associated with JTT-861
Login to view more data
100 Patents (Medical) associated with JTT-861
Login to view more data
100 Deals associated with JTT-861
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Heart failure with reduced ejection fractionPhase 2
United States
Akros Pharma, Inc.
29 Feb 2024
Heart failure with reduced ejection fractionPhase 2
Bulgaria
Akros Pharma, Inc.
29 Feb 2024
Heart failure with reduced ejection fractionPhase 2
Czechia
Akros Pharma, Inc.
29 Feb 2024
Heart failure with reduced ejection fractionPhase 2
Poland
Akros Pharma, Inc.
29 Feb 2024
Heart failure with reduced ejection fractionPhase 2
Romania
Akros Pharma, Inc.
29 Feb 2024
Heart failure with reduced ejection fractionPhase 2
Spain
Akros Pharma, Inc.
29 Feb 2024
Heart Failure, SystolicPhase 2
United States
Akros Pharma, Inc.
29 Feb 2024
Heart Failure, SystolicPhase 2
Bulgaria
Akros Pharma, Inc.
29 Feb 2024
Heart Failure, SystolicPhase 2
Czechia
Akros Pharma, Inc.
29 Feb 2024
Heart Failure, SystolicPhase 2
Poland
Akros Pharma, Inc.
29 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free